ETHOSOMES DOXYCYCLINE: A PROMISING NANOCARRIER FOR ENHANCED OPHTHALMIC DRUG DELIVERY

Ocular medication delivery research has advanced significantly over the past half-century, forcing researchers to assess the benefits and drawbacks of this delivery method. The most widely utilised preparation for ocular medication delivery is still topical eye drops. This type mainly targets anterior ocular illnesses and has a significant precorneal drug loss because to tear production and natural ocular barriers, even though patients tolerate it well. In ocular therapies, antibiotics are frequently given as ointments or solutions. Their local bioavailability is still below ideal, though, requiring frequent dosing, which may result in adverse effects and diminished therapeutic effectiveness. Sustained-release formulations for the ocular administration of antibiotics have been created in order to get around these restrictions.[1] Ocular barriers and traditional topical forms are the main topics of this review's discussion on ocular administration. It showcases experimental strategies intended to get beyond the restrictions on antibiotic distribution by utilising cutting-edge technology such drug-loaded contact lenses, implants, colloidal systems, and in situ gelling systems. Systems based on nanotechnology, especially Ethosomes, have become a viable tactic among them. An inventive nanocarrier technique that improves ocular medication retention, permeability, and targeted administration is Ethosomes loaded with doxycycline. To treat a variety of eye infections and inflammatory diseases, their lipid-based flexible vesicles may efficiently cross ocular barriers and deliver prolonged release and enhanced bioavailability of doxycycline. This study highlights how these nano systems can preserve labile medications, lower dosage frequency, and provide site-specific delivery, creating new opportunities for efficient antibiotic treatment in the eyes.[1]